M42’s Insights Research Organization and Solutions has launched the UAE’s first genomics-driven clinical trial, working with the Department of Health – Abu Dhabi and Halia T ...

Racura Oncology has treated the first patient in its phase 1 HARNESS‑1 clinical trial of RC220 for EGFR‑mutant non‑small cell ...

The European Commission has approved Sanofi’s Cenrifki (tolebrutinib) for adults with secondary progressive multiple ...

Agomab Therapeutics has announced the design of its phase 2b NOV‑ERA study of ontunisertib in fibrostenosing Crohn’s disease, ...

Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in ...

First immunotherapy approved for LACC in England offers new treatment option for women MSD has welcomed the National Institute for Health and Care Excellence’s recommendation of pembrolizumab ...

When looking to treat erectile dysfunction, there are two commonly used treatment options available for patients. These are Viagra and sildenafil: two similar but distinct types of medication. Both ...

Breakwater phase 3 data show significant gains in progression‑free survival Laboratoires Pierre Fabre has secured European Commission approval for Braftovi (encorafenib) in combination with cetuximab ...

Compressed air is among the largest energy expenses in pharmaceutical manufacturing and must remain entirely contamination-free.

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...

New authorisation offers additional option for patients with lvef ≥40% Bayer has received MHRA approval for Kerendia (finerenone) for adults in the UK with symptomatic chronic heart failure and a left ...

A widely recognised impact of the pandemic on the clinical trials landscape has been the increasing use of JIT methods for clinical trial supply and distribution, with many organizations compelled to ...